Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Allarity Therapeutics Q3 2026 Results: Net Loss of $6.2M, Loss Widens

For the nine months ended September 30, 2026, Allarity Therapeutics reported a net loss of $12.4 million, an increase from the $7.9 million loss in the prior year period, primarily driven by higher research and development costs. The company's total stockholders' equity turned to a deficit of $2.3 million as of September 30, 2026, while cash and restricted cash increased to approximately $24.1 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Net income-6.2-2.8
EPS (diluted, $ a share)$-0.39$-0.19

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ALLR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Allarity Therapeutics, Inc.: key numbers

Share price
$0.8410Close, Nov 17
Market cap
$13.5M
Shares outstanding
16MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Allarity Therapeutics, Inc.

All →
7:51 AM ET 8-K
Loan & Debt

Allarity Therapeutics $3M Debt Financing with Streeterville Capital, LLC

Allarity Therapeutics entered into an exchange agreement with Streeterville Capital to partition $3.0 million from an existing $10.93 million promissory note. The partitioned debt was exchanged for 3,000 shares of newly designated Series B Preferred Stock, effectively reducing the company's outstanding debt balance by $3.0 million. The Series B Preferred Stock carries a 9% annual dividend and ranks senior to common stock in liquidation.

Value
$3M
Counterparty
Streeterville Capital, LLC
8:01 AM ET 8-K
Contract Win

Allarity Therapeutics Wins Contract from unnamed European biotechnology company

Allarity Therapeutics secured its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy. The company will provide development and validation services to support a European biotechnology company's precision oncology predictive device in the U.S. market.

Counterparty
unnamed European biotechnology company
4:06 PM ET 8-K
Deal Termination

Allarity Therapeutics Deal Termination with Tumim Stone Capital LLC

Allarity Therapeutics terminated its Common Stock Purchase Agreement with Tumim Stone Capital, effective October 28, 2026. The agreement had allowed the company to sell up to $6.0 million of common stock at its discretion, but Allarity elected to cancel the facility to pursue alternative financing arrangements. No early termination penalties were incurred as a result of the cancellation.

Counterparty
Tumim Stone Capital LLC
8:00 AM ET 8-K
Business Update

Allarity Therapeutics Business Update

Allarity Therapeutics provided an operational update regarding its proprietary Drug Response Predictor (DRP) technology, patent portfolio, and in-house laboratory capabilities. The company highlighted that higher DRP scores were associated with longer overall survival in ovarian cancer patients treated with stenoparib, supporting its strategy to use the technology for patient selection in upcoming pivotal trials.

8:01 AM ET 8-K
Business Update

Allarity Therapeutics Business Update

Allarity Therapeutics has expanded its in-house medical laboratory capabilities to include proteomics and cell line research. These new capabilities will support deeper mechanism-of-action research for its lead asset, stenoparib, and allow the company to offer a broader range of research services to external partners. The expansion is expected to create cost efficiencies without impacting the company's current cash runway.

8:00 AM ET 8-K
Other 8-K Filing

Allarity Therapeutics Other 8-K Filing

Allarity Therapeutics has been granted Japanese Patent No. 7917283 by the Japan Patent Office, covering its proprietary stenoparib-specific Drug Response Predictor (DRP) companion diagnostic. The patent provides intellectual property protection in Japan through 2039 for methods of predicting clinical benefit and selecting patients for stenoparib treatment. This follows similar patent protections already secured in the United States, Europe, and Australia.

Counterparty
Japan Patent Office
Term
through 2039

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.